TriSalus Life Sciences (NASDAQ:TLSI) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) from a sell rating to a hold rating in a research report sent to investors on Saturday.

TLSI has been the subject of a number of other reports. Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. Canaccord Genuity Group lowered their price target on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a report on Friday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $7.00.

TriSalus Life Sciences Trading Down 6.3%

Shares of NASDAQ:TLSI opened at $4.47 on Friday. TriSalus Life Sciences has a 12-month low of $3.42 and a 12-month high of $7.95. The business’s fifty day simple moving average is $5.36 and its 200-day simple moving average is $5.36. The company has a market capitalization of $223.77 million, a PE ratio of -2.44 and a beta of 0.42.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $13.21 million for the quarter, compared to analysts’ expectations of $13.20 million. Research analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current year.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TLSI. AWM Investment Company Inc. acquired a new stake in TriSalus Life Sciences in the 2nd quarter worth approximately $6,812,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of TriSalus Life Sciences in the second quarter worth $29,000. Connective Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 12.8% during the second quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after buying an additional 3,717 shares during the last quarter. Man Group plc acquired a new stake in TriSalus Life Sciences during the 4th quarter worth about $102,000. Finally, Abel Hall LLC purchased a new stake in TriSalus Life Sciences during the 4th quarter valued at about $73,000. 2.58% of the stock is currently owned by hedge funds and other institutional investors.

TriSalus Life Sciences News Summary

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: Q4 results slightly beat expectations — TLSI reported ($0.12) EPS vs. a ($0.13) consensus and revenue of $13.21M vs. $13.20M expected, a small but constructive beat that supports near‑term operational momentum. Earnings Call Highlights
• Positive Sentiment: Company reaffirmed FY2026 revenue guidance of $60M–$62M and said it is expanding its PEDD portfolio — guidance above Street revenue consensus may support longer‑term growth expectations. Guidance & PEDD Expansion
• Positive Sentiment: Brokerage support remains: Lake Street reaffirmed its buy stance, keeping institutional endorsement visible to investors. Lake Street Rating
• Neutral Sentiment: Full earnings call transcripts and coverage are available (useful for detail but not new headline items) — investors can review management commentary on growth initiatives and margins. Earnings Call Transcript
• Neutral Sentiment: Independent estimates and models updated by firms such as Northland provide refreshed forecasts but contain no single consensus surprise; these are reference points for investors modeling FY2026. Northland Estimates
• Negative Sentiment: Canaccord cut its price target from $12 to $7 while keeping a buy rating — the sizable downgrade in upside reduces some analyst‑driven upside expectations and likely pressured the stock despite the buy rating. Canaccord Price Target Cut

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.